Medicus Pharma FY26 Q2 net loss widens 89.1% to $11.68 million
MDCX•Clinical and regulatory updates
The FDA issued a “Study May Proceed” letter for SkinJect’s SKNJCT-005 Phase 2b registrational trial; the UAE DOH authorized Teverelix PRECISION-E2 Phase 2a.
Q2 loss widens as expenses rise
Medicus Pharma posted a Q2 net loss of USD 11.68 million, widening from USD 6.18 million a year earlier.
Operating loss widened to USD 11.48 million as total operating expenses rose 90.8% to USD 11.48 million.
General and administrative costs climbed 43.6% to USD 6.57 million; R&D spending more than doubled to USD 4.91 million.
Cash position and working capital
Cash and cash equivalents were USD 15.17 million at June 30, with USD 10.02 million of restricted cash and working capital of USD 6.14 million.
